Efficacy of Unrelated Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia: A Single-Center Retrospective Study.
- 1Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Abstract
To evaluate the efficacy of unrelated allogeneic hematopoietic stem cell transplantation (URD-HSCT) in severe aplastic anemia (SAA), this study retrospectively analyzed the clinical data of 206 patients at a single center. The median age was 28 years (range: 5-64 years), and 13.6% had received immunosuppressive therapy prior to transplantation. The median time to neutrophil and platelet engraftment was 12 days (range: 9-22 days / 8-55 days), respectively, with a graft failure rate of 3.4%. The cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) was 21.7% (95% CI: 16.6%-27.8%), and that of chronic GVHD was 20.4% (95% CI: 15.4%-26.6%). Survival analysis revealed a 7-year overall survival (OS) rate of 91% for the entire cohort. Notably, the 7-year OS rate was significantly higher in the donor age ≤30 years group compared to the >30 years group (97% vs 85%, P = 0.0028), and in the HLA 10/10 matched group compared to the 9/10 matched group (95% vs 86%, P = 0.023). Multivariate analysis identified donor age >30 years, and HLA 9/10 matching as independent risk factors for OS and graft-versus-host disease-free, relapse-free survival (GRFS). URD-HSCT is an effective treatment for SAA, and selecting an appropriate donor can improve treatment outcomes.
Related
- Rectal colonization with multidrug-resistant organisms in adult acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective, longitudinal, single-center study
- Addition of thiotepa to total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute leukemia and lymphoma: a propensity score-matched retrospective study.
- The role of allogeneic hematopoietic stem cell transplantation in adults with mature T‐cell lymphomas
- Case Report: SAPHO syndrome mimicking osseous relapse after haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
- Viral Respiratory Infections Diagnosed by Multiplex PCR after Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Incidence and Outcome
BibTeX
@article{zhao2026efficacy,
title = {{Efficacy of Unrelated Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia: A Single-Center Retrospective Study.}},
author = {Jinrong Zhao and Liangliang Wu and Ming Zhou and Xiaowei Chen and Wenjian Mo and Ruiqing Zhou and Yumiao Li and Caixia Wang and Shilin Xu and Shiyi Pan and Wei Zhou and Tingfen Deng and Yuping Zhang and Shunqing Wang},
journal = {International journal of medical sciences},
year = {2026},
month = sep,
doi = {10.7150/ijms.137416},
url = {https://europepmc.org/article/MED/42910131},
note = {CC BY},
}
RIS
TY - JOUR
TI - Efficacy of Unrelated Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia: A Single-Center Retrospective Study.
AU - Jinrong Zhao
AU - Liangliang Wu
AU - Ming Zhou
AU - Xiaowei Chen
AU - Wenjian Mo
AU - Ruiqing Zhou
AU - Yumiao Li
AU - Caixia Wang
AU - Shilin Xu
AU - Shiyi Pan
AU - Wei Zhou
AU - Tingfen Deng
AU - Yuping Zhang
AU - Shunqing Wang
PY - 2026
DA - 2026/09/11
JO - International journal of medical sciences
DO - 10.7150/ijms.137416
UR - https://europepmc.org/article/MED/42910131
AB - To evaluate the efficacy of unrelated allogeneic hematopoietic stem cell transplantation (URD-HSCT) in severe aplastic anemia (SAA), this study retrospectively analyzed the clinical data of 206 patients at a single center. The median age was 28 years (range: 5-64 years), and 13.6% had received immunosuppressive therapy prior to transplantation. The median time to neutrophil and platelet engraftment was 12 days (range: 9-22 days / 8-55 days), respectively, with a graft failure rate of 3.4%. The cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) was 21.7% (95% CI: 16.6%-27.8%), and that of chronic GVHD was 20.4% (95% CI: 15.4%-26.6%). Survival analysis revealed a 7-year overall survival (OS) rate of 91% for the entire cohort. Notably, the 7-year OS rate was significantly higher in the donor age ≤30 years group compared to the >30 years group (97% vs 85%, P = 0.0028), and in the HLA 10/10 matched group compared to the 9/10 matched group (95% vs 86%, P = 0.023). Multivariate analysis identified donor age >30 years, and HLA 9/10 matching as independent risk factors for OS and graft-versus-host disease-free, relapse-free survival (GRFS). URD-HSCT is an effective treatment for SAA, and selecting an appropriate donor can improve treatment outcomes.
SN - 1449-1907
ER -